Loading...
Market
What will be BioAge Labs' market capitalization by December 31, 2024?
3
Resolution / Starting Odds
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Stock market data from reliable financial sources such as Bloomberg, Yahoo Finance, or NASDAQ
Story
BioAge Labs Raises $198M in Upsized IPO at $18 Midpoint for Obesity Drug Research
Sep 26, 2024, 03:40 AM
BioAge Labs, a weight-loss drug developer, has successfully raised $198 million through its upsized U.S. initial public offering (IPO), pricing its shares at the midpoint of $18 each. The company aims to use the funds to advance its anti-obesity drug research, particularly focusing on its muscle-building obesity drug candidate, azelaprag. The IPO was upsized again due to increased demand, reflecting investor confidence in BioAge Labs' pivot to obesity drug research.
View original story
Similar markets
Above $1 billion • 25%
Between $750 million and $1 billion • 25%
Between $500 million and $750 million • 25%
Below $500 million • 25%
Above $25 • 25%
Between $20 and $25 • 25%
Between $15 and $20 • 25%
Below $15 • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Above $100 million • 25%
Between $50 million and $100 million • 25%
Between $10 million and $50 million • 25%
Below $10 million • 25%
Yes • 50%
No • 50%
Decrease by more than 20% • 25%
Change between -20% and +20% • 25%
Increase by 20% to 50% • 25%
Increase by more than 50% • 25%
Less than $10 • 25%
$10 to $20 • 25%
$20 to $30 • 25%
More than $30 • 25%
Below $1 Billion • 25%
$1 Billion to $2 Billion • 25%
$2 Billion to $3 Billion • 25%
Above $3 Billion • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%